| Study Period | 2020 - 2030 |
| Market Size (2025) | USD 1.20 Billion |
| Market Size (2030) | USD 2.24 Billion |
| CAGR (2025 - 2030) | 13.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players-market---growth,-trends,-and-forecast-(2020---2025)/closed-system-transfer-devices-(cstd)-market---growth,-trends,-and-forecast-(2020---2025)_Closed_System_Transfer_Devices_Companies.webp "Closed System Transfer Devices (CSTD) Market Major Players")
*Disclaimer: Major Players sorted in no particular order |
Closed System Transfer Devices (CSTD) Market Analysis
The Closed System Transfer Devices Market size is estimated at USD 1.20 billion in 2025, and is expected to reach USD 2.24 billion by 2030, at a CAGR of 13.20% during the forecast period (2025-2030).
The closed system transfer devices market is growing at a high rate owing to factors such as the increasing prevalence of cancer along with the rising oncology product approvals. For instance, a report from the World Health Organization in February 2024 highlighted that in 2022, there were over 20 million new cancer cases worldwide, with 53.5 million individuals surviving at least five years post-diagnosis. Lung cancer was the most prevalent, accounting for 12.4% of new cases, followed closely by female breast cancer (11.6%), colorectal cancer (9.6%), prostate cancer (7.3%), and stomach cancer (4.9%). Given this high incidence and diversity of cancers, there is a pronounced need for protective measures in chemotherapy drug administration. This urgency is driving the demand for closed-system transfer devices, which are engineered to reduce exposure and ensure safe handling.
Minimizing exposure to hazardous drugs and chemicals is crucial, given the potential risks to both healthcare workers and patients. In response to rising incidents of hazardous drug exposures, regulatory authorities in numerous countries have ramped up initiatives to safeguard both patients and healthcare professionals. For instance, in May 2022, Pulse NeedleFree Systems unveiled a new line of disposable needle-free vaccination devices. These devices boast the advantages of needle-free technology, are user-friendly with a plug-and-play design, and are priced similarly to traditional syringes and needles.
Similarly, Zydus Cadila, in February 2022, commenced supplying its needle-free anti-COVID vaccine, ZyCoV-D, to the Indian government. Such regulatory focus on curbing hazardous drug exposure, coupled with innovations like needle-free vaccination solutions, is amplifying the demand for closed-system transfer devices. These devices ensure safer handling and containment of hazardous materials in clinical environments.
In conclusion, the confluence of rising cancer rates, an increase in oncology product approvals, and a regulatory push to mitigate hazardous drug exposure is significantly fueling the demand for closed-system transfer devices. This trend not only bolsters safety in clinical settings but also drives the market's expansion.
Nonetheless, the implementation of closed-system transfer devices comes with a hefty price tag, directly inflating treatment and product costs. Additionally, stringent regulatory policies potentially challenge the market's growth in the coming years.
Closed System Transfer Devices (CSTD) Market Trends
The Needleless System Transfer Devices Segment is Expected to Witness Significant Growth Over the Forecast Period
Driven by advantages such as needle-free medication transfer, product innovations, and enhanced safety, the needleless system segment is anticipated to achieve significant growth. The ease of use and minimized contamination risks associated with needleless transfer devices are expected to propel their adoption throughout the forecast period.
Chronic diseases, including diabetes, cancer, heart disease, and stroke, have seen a notable rise in prevalence. Lifestyle-related ailments, such as chronic lung and kidney diseases, along with Alzheimer’s, have also surged over the last decade. For instance, a February 2024 report from the Centers for Disease Control and Prevention highlighted that approximately 129 million Americans are affected by major chronic diseases, including heart disease, cancer, and diabetes. This prevalence has shown a consistent upward trend over the past 20 years and is expected to continue. Furthermore, a significant portion of the American population is contending with multiple chronic conditions: 42% manage two or more, and 12% face five or more. Such rising chronic disease prevalence is driving innovations in the needleless drug delivery system.
The growing prevalence of chronic diseases, notably cancer and diabetes, is poised to fuel market growth. For instance, a December 2023 report from the Australian Bureau of Statistics noted that in 2022, diabetes impacted 5.3% of the population, translating to 1.3 million individuals. This marks a gradual increase from 3.3% in 2001. Diabetes prevalence, as with many chronic conditions, escalates with age: 1.0% in those aged 0–44 years jumps to 18.7% for those 75 and older. Gender-wise, prevalence rates were similar, with 5.8% of males and 4.9% of females affected. Given these statistics, especially the pronounced rise in older demographics, the needleless system transfer devices segment is poised for growth. These systems promise safer and more efficient medication administration, crucial for managing chronic diseases. Companies like Insujet, offering needle-free solutions for insulin therapy, further bolster the segment's growth prospects.
In conclusion, the confluence of rising chronic disease prevalence, the benefits of needle-free medication, and ongoing innovations in needleless drug delivery systems is set to propel the growth of the needleless system transfer devices segment in the coming years.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is poised to command a significant share of the closed system transfer devices market. This growth is largely driven by proactive measures from the United States Food and Drug Administration and other regulatory bodies in the region, all aimed at bolstering patient safety. Additionally, the surge in oncology drug approvals further fuels this momentum. With an uptick in cancer research and a rising cancer prevalence, the region is set for notable growth.
Moreover, the regional adoption of closed-system transfer devices to manage hazardous drugs, alongside relentless efforts from both public and private entities, is expected to further propel this growth. Chronic diseases, with cancer being a primary concern, are on the rise in North America. A report from the National Cancer Institute in May 2024 highlighted that the U.S. anticipates around 2 million new cancer diagnoses in 2024. Prostate, lung, and colorectal cancers will account for nearly half of male diagnoses, while breast, lung, and colorectal cancers will dominate female diagnoses. With an annual cancer incidence rate of 440.5 cases per 100,000 people, the pressing need for novel drug delivery systems becomes evident, signaling a robust market growth.
Various strategies adopted by major players in the North America closed system transfer devices market are also expected to propel the growth of the market. For instance, in January 2022, ICU Medical Inc. finalized its acquisition of Smiths Medical from Smiths Group plc. This acquisition brought in a diverse portfolio, including syringe and ambulatory infusion devices, vascular access, and vital care products. With projected pro forma revenues hitting USD 2.5 billion, this merger solidifies their stance as a leading infusion therapy provider. Such strategic moves are set to amplify advancements and demand in the closed system transfer devices market, prioritizing safety and efficacy in medication transfers.
Similarly, in December 2024, Zephyrus Innovations launched VaporShield, the first injectable closed system transfer device, at the Partnership Opportunities in Drug Delivery (PODD) conference, addressing critical safety needs for subcutaneous and intra-muscular injections under USP800 legislation. This innovative device offers comprehensive protection against hazardous drug exposure while integrating safety syringe features to prevent needlestick injuries. The launch of VaporShield is expected to drive significant growth in the closed system transfer devices market by fulfilling a critical regulatory and safety gap in healthcare delivery.
In conclusion, the combination of regulatory support, increasing cancer diagnoses, rising chronic disease prevalence, and strategic corporate moves positions North America for substantial growth in the closed system transfer devices market, driven by heightened safety needs and demand for advanced drug delivery systems.
Get Analysis on Important Geographic Markets
Download PDF
Closed System Transfer Devices (CSTD) Industry Overview
The global closed system transfer devices market is moderately consolidated and competitive. Market players are focusing on new product launches, product innovations, and geographical expansion. The key market players operating in the market include Becton, Dickinson and Company, ICU Medical, Inc., Caragen Ltd., Baxter International Inc., and B. Braun Melsungen AG among others.
Closed System Transfer Devices (CSTD) Market Leaders
-
Becton, Dickinson and Company
-
ICU Medical, Inc.
-
Caragen Ltd.
-
Baxter International Inc.
-
B. Braun Melsungen AG
- *Disclaimer: Major Players sorted in no particular order
_Market.webp "Closed System Transfer Devices (CSTD) Market Concentration")
Need More Details on Market Players and Competiters?
Download PDF
Closed System Transfer Devices (CSTD) Market News
- September 2024: Heron Therapeutics, Inc. informed that the U.S. Food and Drug Administration approved its Prior Approval Supplement Application for ZYNRELEF (bupivacaine and meloxicam) extended-release solution VAN, which replaces the current vented vial spike and simplifies aseptic preparation. The streamlined design of the VAN, enhancing safety and adoption, could contribute to the growth of the closed system transfer devices market by improving preparation efficiency and user experience.
- October 2023: EQUASHIELD received additional FDA clearance for the full volume use of its EQUASHIELD Syringe Unit. This advancement is expected to drive growth in the closed system transfer devices market by expanding the range of applications and enhancing safety protocols in handling hazardous drugs.
Closed System Transfer Devices (CSTD) Industry Segmentation
Closed system transfer devices (CSTD) are drug transfer devices that are used to restrict the exposure of hazardous and harmful drugs or vapors to the outer environment. These devices ensure patient/healthcare workers' safety during the usage of hazardous drugs/chemicals.
The closed system transfer devices (CSTD) market is segmented by type, closing mechanism, component, technology, end user, and geography. The type segment is further segmented into needless systems and membrane-to-membrane systems. The closing mechanism segment is further divided into color-to-color alignment systems, Lueker lock systems, push-to-turn systems, and click-to-lock systems. The component segment is further segmented into syringe safety devices, vial access devices, bag access devices, and others. The end-user segment is further divided into hospitals, oncology centers, and others. The geography segment is further segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Type | Needless Systems | ||
| Membrane to Membrane Systems | |||
| By Closing Mechanism | Color to Color Alignment Systems | ||
| Lueker Lock Systems | |||
| Push to Turn systems | |||
| Click to Lock Systems | |||
| By Component | Syringe Safety Devices | ||
| Vial Access Devices | |||
| Bag Access Devices | |||
| Others | |||
| By Technology | Compartmentalize Devices | ||
| Diaphragm Based Devices | |||
| Air Filtration Devices | |||
| By End-User | Hospitals | ||
| Oncology Centers | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Closed System Transfer Devices (CSTD) Market Research FAQs
How big is the Closed System Transfer Devices Market?
The Closed System Transfer Devices Market size is expected to reach USD 1.20 billion in 2025 and grow at a CAGR of 13.20% to reach USD 2.24 billion by 2030.
What is the current Closed System Transfer Devices Market size?
In 2025, the Closed System Transfer Devices Market size is expected to reach USD 1.20 billion.
Who are the key players in Closed System Transfer Devices Market?
Becton, Dickinson and Company, ICU Medical, Inc., Caragen Ltd., Baxter International Inc. and B. Braun Melsungen AG are the major companies operating in the Closed System Transfer Devices Market.
Which is the fastest growing region in Closed System Transfer Devices Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Closed System Transfer Devices Market?
In 2025, the North America accounts for the largest market share in Closed System Transfer Devices Market.
What years does this Closed System Transfer Devices Market cover, and what was the market size in 2024?
In 2024, the Closed System Transfer Devices Market size was estimated at USD 1.04 billion. The report covers the Closed System Transfer Devices Market historical market size for years: 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Closed System Transfer Devices Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
